癌治療向けモノクローナル抗体の新製品と市場

Abstract

In 2003, the Market for Monoclonal Antibodies in the treatment of Cancer is just short of $2.8 billion and growing at a phenomenal rate. The market is fueled by leading products such as Rituxan and Herceptin; however, other products continue to demand more attention each year. This study reviews market data for the years 2001 to the present and forecasts the market to 2008, including Kalorama’s estimates of the competitive market share in 2008 based on the current pipeline and likely market conditions. Although the primary markets considered in the study are the United States and Europe, estimates of other significant international regions are included.

Products in research and development play a vital part in the continued growth of this market. There are approximately six serious products in Phase III development and another six in Phase II. Other areas of focus for this study include demographics and statistics for cancer, corporate profiles for leading and emerging companies, and product pipeline by development stage. With more than 10 million new cancer cases each year and approximately 50 percent of these in the growing 55 and over population, innovative treatments in cancer will continue to grow at phenomenal rates.

This study represents the second volume in a series of reports on advanced cancer therapeutics. The first volume, The Emerging Cancer Vaccines Market, was published in February 2004; the next will cover other immunomodulators and is due out in June 2004.

Table of Contents

1 Executive Summary

1.1 Introduction

1.2 Scope and Methodology

1.3 Size and Growth of the Market

2 Introduction

2.1 History and Growth of the Cancer Treatment Market: Monoclonal Antibody Discovery

2.2 The Role of Biotechnology in Cancer Treatment

2.3 Monoclonal Antibody Technology

2.4 Industry Structure

2.5 Demographics and Statistics

3 Current Monoclonal Antibodies for Cancer Treatment

3.1 Overview

3.1.1 Description of Cancers with Available Products

3.1.1.1 Breast Cancer

3.1.1.2 Non-Hodgkin’s Lymphoma

3.2 Description of Products

3.2.1 Bexxar

3.2.2 Herceptin

3.2.3 Rituxan

3.2.4 Zevalin

3.3 Market Size and Growth

3.4 Competitive Analysis

4 Emerging Monoclonal Antibodies for Cancer Treatment

4.1 Overview

4.1.1 Description of Cancers with New Product Opportunities

4.1.1.1 Colon Cancer

4.1.1.2 Head/Neck Cancer

4.1.1.3 Leukemia

4.1.1.4 Lung Cancer

4.1.1.5 Melanoma

4.1.1.6 Multiple Myeloma

4.1.1.7 Ovarian Cancer

4.1.1.8 Pancreatic Cancer

4.1.1.9 Prostate Cancer

4.1.1.10 Stomach Cancer

4.1.1.11 Other Cancers

4.2 Monoclonal Antibody Pipeline (Cancer)

4.2.1 Phase III

4.2.2 Phase II

4.2.3 Phase I

4.2.4 Pre-clinical

4.3 Market and Product Launch Forecasts

4.4 Potential Competitors and Analysis, 2008

5 Issues and Trends Affecting the Monoclonal Antibody Market

5.1 Introduction

5.2 Insurance and Reimbursement Issues

5.3 Global Issues

5.4 Strategic Trends and Issues

5.5 Treatment Costs

5.6 Alliances, Acquisitions and Licensing Agreements

5.7 Marketing and Distribution Trends

5.8 Manufacturing Issues

5.9 Diagnostic Applications of Monoclonal Antibodies, an Overview

6 Total Market Size and Forecast

6.1 Overview

6.2 Total Market Size and Forecast

6.3 Competitor Analysis

6.4 Market Analysis

7 Corporate Profiles for Current Developers/Providers of Monoclonal Antibodies for Cancer Treatment

7.1 Introduction

7.2 Biogen IDEC

7.3 Corixa Corporation

7.4 Genentech

7.5 GlaxoSmithKline

8 Company Profiles for the Emerging Monoclonal Antibody Cancer Treatment Market

8.1 Introduction

8.2 Abgenix

8.3 Amgen

8.4 Bristol-Myers

8.5 CellTech

8.6 ILEX Oncology

8.7 Imclone Systems

8.8 ImmunoGen

8.9 Immunomedics

8.10 MedImmune

8.11 Merck & Company

8.12 Peregrine Pharmaceuticals

8.13 Protein Design Labs

8.14 Unither Pharmaceuticals

8.15 Wyeth

9 Appendix: Company Names and Addresses